Tesaro Inc (TSRO) 38.49 $TSRO
TESARO to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:09PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York City on February 12, 2015 at 11:10 AM Eastern time. A live webcast of this presentation will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the conference.
TSRO: 38.49 (-0.83)
TESARO to Announce Fourth-Quarter 2014 Financial Results on February 19, 2015
GlobeNewswire - Thu Feb 05, 3:09PM CST
TESARO, Inc. (Nasdaq:TSRO) will announce its fourth-quarter 2014 financial results on Thursday, February 19, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on February 19, 2015 to discuss the Company's results in greater detail.
TSRO: 38.49 (-0.83)
Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020
M2 - Wed Jan 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/8zvsf9/cinv_existing_and) has announced the addition of the "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. H owever, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020. North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million) Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Company Profiles - GlaxoSmithKline plc - Helsinn Holding S.A. - Heron Therapeutics, Inc. - Merck & Co., Inc. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/8z...isting_and
TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99)
CORRECTING and REPLACING -- TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015
GlobeNewswire - Mon Jan 12, 10:54AM CST
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015
TSRO: 38.49 (-0.83)
TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015
GlobeNewswire - Mon Jan 12, 7:00AM CST
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015
TSRO: 38.49 (-0.83)
Pfizer Licenses Opko's Long-Acting Growth Hormone
at Investor's Business Daily - Mon Dec 15, 11:01AM CST
Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading -- a more than...
TSRO: 38.49 (-0.83), OPK: 13.80 (-0.28), PFE: 34.64 (-0.23)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate
GlobeNewswire - Tue Dec 02, 4:14AM CST
--Candidate Will Target Two Undisclosed Immune Checkpoints
TSRO: 38.49 (-0.83)
TESARO to Present at the 2014 Deutsche Bank BioFEST
GlobeNewswire - Tue Nov 25, 4:00PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at the 2014 Deutsche Bank BioFEST Conference on Tuesday, December 2, 2014 at 4:00 p.m. ET in Boston.
TSRO: 38.49 (-0.83), DB: 32.29 (+0.70)
TESARO to Present at the Nasdaq 31st Investor Program
GlobeNewswire - Tue Nov 25, 7:07AM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Nasdaq 31 Investor Program on Tuesday, December 2, 2014 at 10:15 a.m. GMT in London.
TSRO: 38.49 (-0.83)
Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 2:10PM CST
New data revealed Myriad's (MYGN) myChoice HRD score as an efficient predictor of niraparib sensitivity in patient-derived xenograft models of ovarian cancer
MYGN: 34.03 (+0.40), TSRO: 38.49 (-0.83), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
TESARO and Myriad Announce Companion Diagnostics Collaboration
GlobeNewswire - Thu Nov 20, 6:45AM CST
TESARO, Inc. (Nasdaq:TSRO) and Myriad Genetics (Nasdaq:MYGN) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of TESARO's development of niraparib.
MYGN: 34.03 (+0.40), TSRO: 38.49 (-0.83)
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 381.83 (+4.66), TSRO: 38.49 (-0.83), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), GLD: 117.98 (+0.64), MCD: 95.65 (+0.56), SLV: 16.54 (+0.39), GDX: 21.26 (+0.11), TWTR: 48.50 (+0.55), AAPL: 127.08 (+0.62), BABA: 89.05 (+1.95)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 2.18 (-0.02), NTES: 112.99 (-0.49), CIG: 4.29 (+0.10), TSRO: 38.49 (-0.83), DDD: 32.81 (+0.40), CLDX: 20.97 (+0.53), SCMP: 15.32 (+0.04), BVN: 10.86 (+0.36), ABGB: 15.52 (+0.34), SSE: 5.23 (+0.22)
TESARO to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:00AM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 11:20 a.m. GMT in London.
TSRO: 38.49 (-0.83)
TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 1:31AM CST
TSRO: 38.49 (-0.83)
Tesaro beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:04AM CST
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a third-quarter loss of $36.2 million.
TSRO: 38.49 (-0.83)
Tesaro beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:07PM CST
TSRO: 38.49 (-0.83)
TESARO Announces Third-Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 05, 3:36PM CST
-- Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA
TSRO: 38.49 (-0.83)
Tesaro reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:34PM CDT
TSRO: 38.49 (-0.83)
TESARO to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:09PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York City on February 12, 2015 at 11:10 AM Eastern time. A live webcast of this presentation will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the conference.
TSRO: 38.49 (-0.83)
TESARO to Announce Fourth-Quarter 2014 Financial Results on February 19, 2015
GlobeNewswire - Thu Feb 05, 3:09PM CST
TESARO, Inc. (Nasdaq:TSRO) will announce its fourth-quarter 2014 financial results on Thursday, February 19, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on February 19, 2015 to discuss the Company's results in greater detail.
TSRO: 38.49 (-0.83)
Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020
M2 - Wed Jan 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/8zvsf9/cinv_existing_and) has announced the addition of the "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. H owever, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020. North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million) Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Company Profiles - GlaxoSmithKline plc - Helsinn Holding S.A. - Heron Therapeutics, Inc. - Merck & Co., Inc. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/8z...isting_and
TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99)
CORRECTING and REPLACING -- TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015
GlobeNewswire - Mon Jan 12, 10:54AM CST
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015
TSRO: 38.49 (-0.83)
TESARO Announces Expansion of Niraparib Clinical Program and Outlines Late-Stage Program Milestones for 2015
GlobeNewswire - Mon Jan 12, 7:00AM CST
-- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015
TSRO: 38.49 (-0.83)
Pfizer Licenses Opko's Long-Acting Growth Hormone
at Investor's Business Daily - Mon Dec 15, 11:01AM CST
Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading -- a more than...
TSRO: 38.49 (-0.83), OPK: 13.80 (-0.28), PFE: 34.64 (-0.23)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate
GlobeNewswire - Tue Dec 02, 4:14AM CST
--Candidate Will Target Two Undisclosed Immune Checkpoints
TSRO: 38.49 (-0.83)
TESARO to Present at the 2014 Deutsche Bank BioFEST
GlobeNewswire - Tue Nov 25, 4:00PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at the 2014 Deutsche Bank BioFEST Conference on Tuesday, December 2, 2014 at 4:00 p.m. ET in Boston.
TSRO: 38.49 (-0.83), DB: 32.29 (+0.70)
TESARO to Present at the Nasdaq 31st Investor Program
GlobeNewswire - Tue Nov 25, 7:07AM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Nasdaq 31 Investor Program on Tuesday, December 2, 2014 at 10:15 a.m. GMT in London.
TSRO: 38.49 (-0.83)
Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 2:10PM CST
New data revealed Myriad's (MYGN) myChoice HRD score as an efficient predictor of niraparib sensitivity in patient-derived xenograft models of ovarian cancer
MYGN: 34.03 (+0.40), TSRO: 38.49 (-0.83), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
TESARO and Myriad Announce Companion Diagnostics Collaboration
GlobeNewswire - Thu Nov 20, 6:45AM CST
TESARO, Inc. (Nasdaq:TSRO) and Myriad Genetics (Nasdaq:MYGN) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of TESARO's development of niraparib.
MYGN: 34.03 (+0.40), TSRO: 38.49 (-0.83)
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 381.83 (+4.66), TSRO: 38.49 (-0.83), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), GLD: 117.98 (+0.64), MCD: 95.65 (+0.56), SLV: 16.54 (+0.39), GDX: 21.26 (+0.11), TWTR: 48.50 (+0.55), AAPL: 127.08 (+0.62), BABA: 89.05 (+1.95)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 2.18 (-0.02), NTES: 112.99 (-0.49), CIG: 4.29 (+0.10), TSRO: 38.49 (-0.83), DDD: 32.81 (+0.40), CLDX: 20.97 (+0.53), SCMP: 15.32 (+0.04), BVN: 10.86 (+0.36), ABGB: 15.52 (+0.34), SSE: 5.23 (+0.22)
TESARO to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:00AM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 11:20 a.m. GMT in London.
TSRO: 38.49 (-0.83)
TESARO's (TSRO) CEO Lonnie Moulder on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 1:31AM CST
TSRO: 38.49 (-0.83)
Tesaro beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:04AM CST
WALTHAM, Mass. (AP) _ Tesaro Inc. (TSRO) on Thursday reported a third-quarter loss of $36.2 million.
TSRO: 38.49 (-0.83)
Tesaro beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:07PM CST
TSRO: 38.49 (-0.83)
TESARO Announces Third-Quarter 2014 Operating Results
GlobeNewswire - Wed Nov 05, 3:36PM CST
-- Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA
TSRO: 38.49 (-0.83)
Tesaro reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:34PM CDT
TSRO: 38.49 (-0.83)
